These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [The role of peroxisome proliferator-activated receptor-γ/nuclear factor-ΚB transduction pathway on coagulation disorders induced by sepsis]. Author: Sun Y, Wang J, Yu L, Dai L. Journal: Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Jun; 27(6):520-4. PubMed ID: 26049195. Abstract: OBJECTIVE: To determine the role of activated status of peroxisome proliferator-activated receptorγ/nuclear factor-ΚB (PPAR-γ/NF-ΚB ) in coagulation disorders induced by sepsis. METHODS: Forty male Sprague-Dawley (SD) rats were randomly divided into four groups, n=10 in each group: control group, lipopolysaccharide (LPS) challenged group, rosiglitazone (ROSI, selective agonist of PPAR-γ) pretreatment group, and GW9662 (PPAR-γ antagonist) pretreatment group. The sepsis model was reproduced by injection of 6 mg/kg LPS via sublingual vein, and the rats in control group were injected with 2 mL/kg normal saline. The rats in ROSI pretreatment group were given 0.3 mg/kg ROSI by sublingual venous injection followed by injection of LPS 30 minutes later; and in GW9662 pretreatment group rats were given 0.3 mg/kg GW9662 by sublingual venous injection followed by 0.3 mg/kg ROSI 15 minutes later, followed by injection of LPS 30 minutes later. Blood was collected at 4 hours after LPS administration, and the expressions of PPAR-γ and NF-ΚBp65 in peripheral blood mononuclear cell (PBMC) were determined with immunocytocheminal technique and graph analysis. Plasma prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), and D-dimer were determined simultaneously. RESULTS: (1) PPAR-γ/NF-ΚB pathway: the expressions of PPAR-γ and NF-ΚBp65 were lowered in control group, and they were expressed in cytoplasm. In LPS challenged group the expression of PPAR-γ (gray value) was slightly increased but with no significant difference as compared with control group (111.01±4.06 vs. 98.46±5.99, P>0.05). In ROSI pretreatment group the expression of PPAR-γ (gray value) was significantly higher than that in LPS challenged group (214.38±5.79 vs. 111.01±4.06, P<0.01), with dislocation into nuclei. In GW9662 pretreatment group the expression of PPAR-γ (gray value) was lowered but without significant difference compared with that of control group (44.21±2.64 vs. 98.46±5.99, P>0.05). In LPS challenged group the expression of NF-ΚBp65 (gray value) was significantly higher than that in control group (249.48±6.86 vs. 105.81±10.19, P<0.01), and it was translocated into the nuclei. In ROSI pretreatment group the expression of NF-ΚBp65 (gray value) was significantly lower than that in LPS challenged group (102.47±8.05 vs. 249.48±6.86, P<0.01), and it lied in cytoplasm. In GW9662 pretreatment group the expression of NF-ΚBp65 (gray value) showed no significant difference as compared with that of LPS challenged group (214.84±7.91 vs. 249.48±6.86, P>0.05). (2) Coagulation: compared with control group, PT and APTT were significantly prolonged, FIB was significantly decreased, and D-dimer was significantly increased in LPS challenged group [PT (s): 18.32±2.03 vs. 12.22±1.38, APTT (s): 40.05±2.72 vs. 26.64±2.73, FIB (g/L): 1.65±0.51 vs. 3.60±0.37, D-dimer (mg/L): 2.58±0.73 vs. 0.37±0.06, all P<0.01]. Compared with LPS challenged group, APTT and PT were significantly shortened, FIB was significantly increased, and D-dimer was significantly lowered in ROSI pretreatment group [PT (s): 13.93±1.67 vs. 18.32±2.03, APTT (s): 30.29±0.86 vs. 40.05±2.72, FIB (g/L): 3.18±0.69 vs 1.65±0.51, D-dimer (mg/L): 0.40±0.12 vs. 2.58±0.73, all P<0.01]. All parameters in GW9662 pretreatment group showed no significant difference as compared with those of LPS challenged group. CONCLUSIONS: PPAR-γ agonist ROSI may ameliorate coagulation disorders in septic rats. PPAR-γ/NF-ΚB transduction pathway plays an important role in septic coagulopathy.[Abstract] [Full Text] [Related] [New Search]